GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001470613 | Prostate | Tumor | striated muscle tissue development | 98/3246 | 384/18723 | 2.96e-05 | 3.56e-04 | 98 |
GO:003629416 | Prostate | Tumor | cellular response to decreased oxygen levels | 49/3246 | 161/18723 | 3.02e-05 | 3.62e-04 | 49 |
GO:001633112 | Prostate | Tumor | morphogenesis of embryonic epithelium | 45/3246 | 147/18723 | 5.34e-05 | 5.83e-04 | 45 |
GO:003514814 | Prostate | Tumor | tube formation | 45/3246 | 148/18723 | 6.41e-05 | 6.95e-04 | 45 |
GO:000756514 | Prostate | Tumor | female pregnancy | 55/3246 | 193/18723 | 7.79e-05 | 8.11e-04 | 55 |
GO:000717815 | Prostate | Tumor | transmembrane receptor protein serine/threonine kinase signaling pathway | 90/3246 | 355/18723 | 7.93e-05 | 8.19e-04 | 90 |
GO:000961214 | Prostate | Tumor | response to mechanical stimulus | 60/3246 | 216/18723 | 8.45e-05 | 8.46e-04 | 60 |
GO:004578714 | Prostate | Tumor | positive regulation of cell cycle | 81/3246 | 313/18723 | 8.45e-05 | 8.46e-04 | 81 |
GO:005127114 | Prostate | Tumor | negative regulation of cellular component movement | 92/3246 | 367/18723 | 1.03e-04 | 9.99e-04 | 92 |
GO:004876213 | Prostate | Tumor | mesenchymal cell differentiation | 64/3246 | 236/18723 | 1.08e-04 | 1.03e-03 | 64 |
GO:007145614 | Prostate | Tumor | cellular response to hypoxia | 45/3246 | 151/18723 | 1.08e-04 | 1.03e-03 | 45 |
GO:000183813 | Prostate | Tumor | embryonic epithelial tube formation | 38/3246 | 121/18723 | 1.09e-04 | 1.03e-03 | 38 |
GO:004666111 | Prostate | Tumor | male sex differentiation | 48/3246 | 165/18723 | 1.25e-04 | 1.16e-03 | 48 |
GO:004470613 | Prostate | Tumor | multi-multicellular organism process | 60/3246 | 220/18723 | 1.47e-04 | 1.34e-03 | 60 |
GO:000184112 | Prostate | Tumor | neural tube formation | 33/3246 | 102/18723 | 1.60e-04 | 1.44e-03 | 33 |
GO:000840612 | Prostate | Tumor | gonad development | 60/3246 | 221/18723 | 1.68e-04 | 1.50e-03 | 60 |
GO:006048513 | Prostate | Tumor | mesenchyme development | 75/3246 | 291/18723 | 1.74e-04 | 1.53e-03 | 75 |
GO:000858411 | Prostate | Tumor | male gonad development | 42/3246 | 141/18723 | 1.83e-04 | 1.61e-03 | 42 |
GO:200014614 | Prostate | Tumor | negative regulation of cell motility | 89/3246 | 359/18723 | 1.99e-04 | 1.74e-03 | 89 |
GO:004654611 | Prostate | Tumor | development of primary male sexual characteristics | 42/3246 | 142/18723 | 2.17e-04 | 1.86e-03 | 42 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CIT | SNV | Missense_Mutation | rs779515686 | c.4130N>T | p.Pro1377Leu | p.P1377L | O14578 | protein_coding | deleterious(0) | benign(0.248) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
CIT | SNV | Missense_Mutation | | c.5132C>T | p.Ser1711Phe | p.S1711F | O14578 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
CIT | SNV | Missense_Mutation | novel | c.2482N>A | p.Glu828Lys | p.E828K | O14578 | protein_coding | deleterious(0.04) | possibly_damaging(0.628) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
CIT | SNV | Missense_Mutation | | c.3097G>T | p.Val1033Leu | p.V1033L | O14578 | protein_coding | tolerated(0.08) | probably_damaging(0.978) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CIT | SNV | Missense_Mutation | rs747447396 | c.2839C>T | p.Arg947Cys | p.R947C | O14578 | protein_coding | deleterious(0.02) | possibly_damaging(0.446) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CIT | SNV | Missense_Mutation | rs747447396 | c.2839N>T | p.Arg947Cys | p.R947C | O14578 | protein_coding | deleterious(0.02) | possibly_damaging(0.446) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CIT | SNV | Missense_Mutation | | c.242N>T | p.Ser81Phe | p.S81F | O14578 | protein_coding | deleterious(0.02) | benign(0.17) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CIT | SNV | Missense_Mutation | novel | c.637N>T | p.His213Tyr | p.H213Y | O14578 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
CIT | SNV | Missense_Mutation | rs368981957 | c.5590N>A | p.Asp1864Asn | p.D1864N | O14578 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CIT | SNV | Missense_Mutation | novel | c.1771N>A | p.Glu591Lys | p.E591K | O14578 | protein_coding | tolerated(0.31) | benign(0.019) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |